What should we to do to insulin in ckd
Reading File
Finding Sources
Finding Sources
Searching PubMed
insulin dose adjustment chronic kidney disease
Finding Sources
Finding Sources
Searching PubMed
insulin management diabetes chronic kidney disease
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive, high-quality information from multiple authoritative textbooks. Here is the full answer:
Insulin in Chronic Kidney Disease (CKD)
The Core Principle: Reduce the Dose
The kidney is responsible for 30-80% of systemic insulin clearance (both endogenous and exogenous). As GFR declines, insulin is degraded and cleared more slowly, leading to accumulation, a prolonged half-life, and a significantly increased risk of hypoglycemia. Therefore, insulin doses need to be reduced as GFR declines.
- Comprehensive Clinical Nephrology, 7th Edition, p. 475
Why Hypoglycemia Risk Increases in CKD
Three concurrent mechanisms make hypoglycemia more dangerous in CKD patients on insulin:
- Reduced insulin clearance - prolonged circulating half-life means insulin stays active longer
- Decreased renal gluconeogenesis - the kidney is a significant contributor to glucose production, especially during fasting; this is impaired in CKD
- Flattening of the HbA1c-to-glucose relationship - HbA1c becomes unreliable at low GFR (due to altered red cell turnover), so glucose targets are harder to monitor accurately
- Brenner & Rector's The Kidney, 2-Volume Set, p. 1804
What This Means Clinically
| Situation | Action |
|---|---|
| Progressive CKD (falling GFR) | Proactively reduce insulin dose; monitor more frequently |
| Severe CKD / ESRD | Expect significantly lower insulin requirements vs. normal kidneys |
| Any BG < 70 mg/dL | Reevaluate scheduled doses immediately; reassess declining renal function as a contributing cause |
| Renal failure (general) | May cause either hyposensitivity or hypersensitivity to insulin - clinical response, not just empiric dosing, guides adjustment |
- The Washington Manual of Medical Therapeutics
- The Harriet Lane Handbook, 23rd ed., p. 1418
Which Insulin Formulations to Use
According to Comprehensive Clinical Nephrology:
- Rapid-acting analogs (aspart, lispro) and long-acting analogs (glargine, detemir) have metabolic profiles that are largely unaffected by CKD itself - these remain the preferred choices
- No single specific insulin regimen is universally recommended for CKD; regimen selection follows the same T1D/T2D principles, but with dose reduction
- For T1D: basal-bolus regimen remains standard
- For T2D: typically start with once or twice daily long-acting insulin, advancing to basal-bolus if needed
Glycemic Targets in CKD
- HbA1c target: 7% or less, but this should be relaxed in patients with significant comorbidities or high hypoglycemia risk
- HbA1c becomes less reliable as a monitoring tool in advanced CKD - continuous glucose monitoring (CGM) is increasingly recommended alongside insulin pumps
- Goldman-Cecil Medicine, p. 3996
Key Point: Insulin vs. Other Antidiabetics in CKD
Insulin is often the preferred agent in advanced CKD precisely because, unlike many oral agents, it can be dose-adjusted freely. By contrast:
- Sulfonylureas: contraindicated at eGFR < 45 (CKD stage 3b or worse) due to hypoglycemia risk from metabolite accumulation
- Metformin: avoid when creatinine > 1.5-1.7 mg/dL due to lactic acidosis risk
- SGLT2 inhibitors: lose efficacy at low eGFR; can be used at higher GFR and offer cardio-renal protection
- GLP-1 agonists: some (e.g., exenatide) require discontinuation at low eGFR
Insulin remains usable across all stages of CKD with appropriate dose reduction and monitoring.
Summary
In CKD, you reduce the insulin dose (progressively as GFR falls), monitor blood glucose more closely, use modern analogs (glargine, lispro, aspart) which are CKD-compatible, and stay vigilant for hypoglycemia - driven by reduced clearance and impaired gluconeogenesis. The dose adjustment is guided by clinical response and glucose monitoring rather than fixed empiric percentages.
This is a shared conversation. Sign in to Orris to start your own chat.